Medicinal Products

Abakavir/lamivudin Mylan Pharma 600 mg/300 mg filmom obložene tablete

Name Abakavir/lamivudin Mylan Pharma 600 mg/300 mg filmom obložene tablete
Former Name Abakavir/lamivudin Vale 600 mg/300 mg filmom obložene tablete
Marketing Authorisation Number HR-H-622715617
Active Substance abacavirum, lamivudinum
Pharmaceutical Form filmom obložena tableta
Strength 600 mg + 300 mg
Packaging [MA Number for Packaging] 30 tableta u blisteru, u kutiji  [HR-H-622715617-01]
30 tableta u blisteru s jediničnom dozom, u kutiji  [HR-H-622715617-02]
90 tableta u blisteru, u kutiji  [HR-H-622715617-03]
30 tableta u blisteru, u kutiji, 3 pakiranja u kutiji  [HR-H-622715617-04]
30 tableta u bočici, u kutiji  [HR-H-622715617-05]
Manufacturer Mylan Hungary Kft, Komárom, Mađarska;
McDermott Laboratories Limited, t/a Gerard Laboratories, t/a Mylan Dublin Dublin 13, Irska
Marketing Authorisation Holder Mylan Ireland Limited, Unit 35/36 Grange Parade, Baldoyle Industrial Estate, Dublin, Irska
Marketing Authorisation Date 31.05.2019
MA Period of Validity 10.08.2023
Classification Number UP/I-530-09/15-01/321
Registration Number 381-12-01/30-19-23
Composition jedna filmom obložena tableta sadrži 600 mg abakavira (u obliku abakavirsulfata) i 300 mg lamivudina
Prescription na recept
Type of prescription ograničeni recept
Distribution u ljekarni
Advertising to general public zabranjeno
ATC Code J05AR02
Medicinal product marketed in the Croatia Ne
SmPC download
PL download
Educational materials
for healthcare professionals
Prezentacija za zdravstvene radnike, verzija 3
Back